[Primary central nervous system lymphoma--a report of 32 cases with literature review]. 2006

Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China.

OBJECTIVE The incidence of primary central nervous system lymphoma (PCNSL) is increasing, and its prognosis is poor. This study was to investigate the clinical features of PCNSL, and evaluate the efficacy of high-dose methotrexate (MTX)-based chemotherapy for immunocompetent Chinese patients with PCNSL. METHODS Clinical data of 32 patients (median age, 50 years) with pathologically confirmed PCNSL were analyzed retrospectively. Before Nov. 2001, CHOP with or without whole brain radiotherapy (WBRT) was employed; after then, high-dose MTX-based chemotherapy with or without WBRT was employed. RESULTS Of the 32 PCNSL patients, 25 (78.1%) were more than 45 years old; 24 (75.0%) suffered intracranial hypertension; 25 (78.1%) had single intracranial mass; no positive case of cerebrospinal fluid (CSF) cellular examination was found; 28 (87.5%) were B-cell lymphoma, among which 19 (59.4%) were diffuse large B-cell lymphoma. Median follow-up of the patients was 13.5 months (1-84 months). Kaplan-Meier test showed that the median overall survival time was 26 months, and the 2-year survival rate was 45.7%. The complete response rate of the 18 patients who received high-dose MTX-based chemotherapy plus WBRT was 61.1%, the median survival time was more than 26 months, and the 2-year survival rate was 65.1%. The efficacy of high-dose MTX-based chemotherapy plus WBRT was better than that of CHOP plus WBRT. Log-rank test showed that the survival time of the patients with performance status (PS) of 0-1 or normal serum lactate dehydrogenase (LDH) was longer than those with PS of 2-3 or elevated LDH. CONCLUSIONS PCNSL often occurs in middle-aged and aged patients, with intracranial hypertension as the main clinical manifestation. B-cell lymphoma is the predominant subtype. High-dose MTX-based chemotherapy plus WBRT is efficient and feasible for PCNSL.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
December 2004, Clinical neurology and neurosurgery,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
January 1991, Oncology,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
December 2002, Neurology India,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
December 2022, Medicine,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
April 2018, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
April 2015, Oncology letters,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
June 1996, Indian journal of cancer,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
April 1989, American journal of clinical oncology,
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
January 2022, Neurocirugia (English Edition),
Ji-Qun Yi, and Tong-Yu Lin, and You-Jian He, and Hui-Qiang Huang, and Zhong-Jun Xia, and Yun-Fei Xia, and Rui-Hua Xu, and Ying Guo, and Zhong-Zhen Guan
January 2014, Case reports in neurology,
Copied contents to your clipboard!